12 09, 2024

Lovesac Stock Jumps 25% on Q2 Earnings Results, But Is This Reason Enough to BUY LOVE?

By |2024-09-17T15:46:35+00:00September 12th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

Lovesac Co. (LOVE) has gained more than 24% so far Thursday morning after delivering a somewhat mixed bag for the second quarter of fiscal 2025. The company saw sales climb, yet profits shrunk.  Still, the company managed to beat the analyst expectations on both the top and bottom lines for Q2. The loss of [...]

11 09, 2024

The Presidential Debate is Affecting Trump’s Media Company: 3 Things DJT Investors Need to See

By |2024-10-21T16:46:24+00:00September 11th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

The debate America has long been anticipating took place last night between former president Donald Trump and current Vice President Kamala Harris.  The general consensus as of Wednesday morning is that Trump put on a somewhat rocky performance, with many believing Harris performed better than expected. Even conservative voters aren’t thrilled with what they [...]

10 09, 2024

What the EU’s Court Verdict Means for Apple: Plus, 3 Other Things for AAPL Investors to Consider

By |2024-10-21T16:46:32+00:00September 10th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

It was a bad day for tech companies in the European Union (EU) court system as both Apple (AAPL) and Google (GOOGL) lost their battles and will face hefty financial penalties as a result. Apple was fighting a €13 billion ($14.4 billion) Irish tax bill, which can be traced all the way back to [...]

6 09, 2024

Vaxcyte Trial Results Suggest it Could Compete With Pfizer: Is it Worth Buying This Stock Today?

By |2024-09-06T17:12:21+00:00September 6th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Earlier this week Vaxcyte (PCVX) shared an update on its VAX-31 trial results, which are quite promising. The stock popped nearly 50% on the news, sending shares to an all-time high of $115/share.  VAX-31 is the company’s pneumococcal conjugate vaccine. This disease can contribute to more serious illnesses such as pneumonia, meningitis, and various [...]

5 09, 2024

Tesla Stock is Up 13% in the Past Week, Outpacing Peers and the Market as a Whole: Time to Buy?

By |2024-09-05T15:42:51+00:00September 5th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

It’s been a rollercoaster ride so far this year for Tesla (TSLA) investors, as the stock has seen thrilling highs and concerning lows.  The stock fell roughly 40% in a single month over the summer, but has since begun its road to recovery. It’s up 17% in the past month, and looks to be [...]

4 09, 2024

Kamala Harris Opposes Nippon’s Acquisition of US Steel: 3 Things Investors Need to Know

By |2024-09-04T17:30:37+00:00September 4th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

Just a few days back during her presidential campaign stop in Pittsburgh, Pennsylvania, Vice President Kamala Harris made it clear where she stands on Nippon’s acquisition of US Steel (X). Nippon Steel agreed to purchase US Steel back in December of 2023 for a price of $14.9 billion. But, Joe Biden - president at [...]

3 09, 2024

Ulta Beauty is Recovering After the Sell-off From Weak Earnings, But is it Time to Buy ULTA Yet?

By |2024-09-03T16:57:43+00:00September 3rd, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , , |

Shares of Ulta Beauty Inc. (ULTA) fell as much as 10% last week after a downtrodden earnings update for the second quarter. This puts it down nearly 13% through 2024 thus far. However, the stock is now only down 3% in the past week after recovering since Thursday. Shares are up more than 2% [...]

30 08, 2024

Lululemon Delivers Weak Q2 Results, Lowers Outlook: Why LULU Investors Shouldn’t Panic Yet

By |2024-08-30T16:04:44+00:00August 30th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

Lululemon Athletica, inc. (LULU) may not have had the second-quarter performance it was hoping for, but the market hasn’t responded with panic yet, and LULU investors shouldn’t either.  The company acknowledged where it’s falling short and has a plan to turn things around. Revenue climbed to $2.37 billion, a 7% improvement from this time [...]

29 08, 2024

Salesforce Delivers on the Top and Bottom Lines in Q2: 3 Reasons to Buy CRM Today

By |2024-08-29T16:51:10+00:00August 29th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

Salesforce (CRM) reported second-quarter earnings and revenue that came in ahead of analyst expectations thanks to a surge in bookings and early renewals for key clients. Here’s how the company performed compared to the consensus: Earnings: $2.56/share compared to the estimate of $2.35/share. Revenue: $9.3 billion compared to the estimate of $9.2 billion. Revenue [...]

28 08, 2024

Shares of Ambarella Climb 11% After Earnings Beat, Guidance Upgrade: Is it Time to Buy AMBA?

By |2024-08-28T17:02:18+00:00August 28th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , , |

Ambarella (AMBA) started Wednesday morning where it left off yesterday, climbing higher on the heels of an earnings beat in the fiscal second quarter. The stock is up 11% so far today and 21% in the past week. This comes after the company delivered a narrower loss than experts were expecting with EPS of [...]

Go to Top